Riboscience, a clinical-stage biotechnology company developing first-in-class immunotherapies, today announced that Phase 1b data for RBS2418, its lead oral ENPP1 inhibitor, will be presented in a ...
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class ...
Summit Therapeutics Inc. announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class investigational PD-1 /VEGF ...
"Next-Generation M&A Encyclopedia - Designing 'Want to Sell and Want to Buy'"Today's Headlines AI Storm transfers two data ...
Tech Times on MSN
Plain-English AI produces validated drug-candidate proteins against rare disease target
AI protein design leapt forward: University of Washington researchers built Prompteina, the first model generating 3D protein ...
AI is accelerating antibiotic discovery, but clinical translation requires standardized data, safety optimization, and new ...
Lithium-metal battery research gets a major advance: scientists at UNIST and KAIST showed two cheap commodity solvents triple ...
Canva has introduced ProSuite, bringing together specialist creative applications and AI-assisted workflows to help ...
Dublin, Oct. 12, 2026 (GLOBE NEWSWIRE) -- "Magnetic Affinity Separation Particle Market in the United States" has been added to ResearchAndMarkets.com's offering. The global magnetic affinity ...
A joint research team from UNIST and KAIST has developed an electrolyte that extends lithium metal battery lifespan by ...
A global competition benchmarked 12,000 AI-designed CD20 binders in primary human CAR-T cells, revealing common design ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results